Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future.

Pharmacology & therapeutics - 1 Aug 2016

Lythgoe Mark P, Rhodes Christopher J, Ghataorhe Pavandeep, Attard Mark, Wharton John, Wilkins Martin R

Abstract excerpt

The past three decades have witnessed a welcome expansion of the therapeutic armamentarium for the management of pulmonary arterial hypertension (PAH). However, against this backdrop, there have been some notable disappointments in drug development. Here we use these as case studies to emphasize the importance of informed drug target selection, the early evaluation of dose-response relationships in human studies,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Disease Models, Animal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Drug Combinations

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypertension, Pulmonary

Share to Protein-Tyrosine Kinases

Share to Vasoactive Intestinal Peptide

Source

Identifiers

PMID: 27133570
DOI: 10.1016/j.pharmthera.2016.04.012

Genes

PAH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future.PMID 27133570Read ↗

Pulmonary arterial hypertension - progress in understanding the disease and prioritizing strategies for drug development.Semantic proximity Read ↗

Recent advances in pulmonary arterial hypertensionSemantic proximity Read ↗

Advances in diagnosis and patient profiling in pulmonary arterial hypertension for precision medicine.Semantic proximity Read ↗

Using Omics to Understand and Treat Pulmonary Vascular DiseaseSemantic proximity Read ↗

Genetics and pharmacogenomics in pulmonary arterial hypertension.Semantic proximity Read ↗

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.Semantic proximity Read ↗

Artificial Intelligence and Multi-Omics Integration in the Precision Management of Pulmonary Hypertension: From Early Diagnosis to Therapeutic StratificationSemantic proximity Read ↗

CTRP7 as a Molecular Biomarker for Predicting Responsiveness to Pulmonary Vasodilators: Insights from Human and Animal Studies in Pulmonary Arterial HypertensionSemantic proximity Read ↗

Individualized Interactomes from Pulmonary Arterial Hypertension Cell Biopsies Predict Therapeutic ResponseSemantic proximity Read ↗

Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.Semantic proximity Read ↗

StratosPHere 2: A response-adaptive randomised placebo-controlled Phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2Semantic proximity Read ↗

StratosPHere 2: study protocol for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.